What to Record After a Reaction to Polynucleotide Injectables

Why Recording Reactions Matters

Recording any adverse reaction following a polynucleotide injectable is important for several reasons. First, it supports your own medical care, providing a clear timeline and symptom history if you need further help. Second, it contributes to collective safety knowledge, since polynucleotide injectables are unlicensed in the UK and their safety profile is still being established. Reporting helps regulatory authorities monitor patterns, identify risks, and take action if needed. This is particularly relevant for substances with evolving evidence, as highlighted by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Polynucleotide injectables are a relatively new class of aesthetic treatments and do not have the same established safety track record as licensed medicines. Because of this, adverse reaction data is especially valuable. Without consistent reporting, potential safety concerns might go unnoticed. Your report can help regulators and practitioners identify whether certain reactions are isolated or part of a broader trend. This collective evidence can inform future guidance, warnings, or regulatory action, and may even influence the licensing process for these products in the UK.

In addition, keeping your own record ensures that, if you need to see a healthcare professional, you can provide them with accurate information. This can be critical for appropriate treatment and for distinguishing between mild, expected side effects and more serious reactions that require intervention.

What Details to Record

When recording a reaction, include as much specific information as possible. Essential details are:

• Date and time of the reaction
• Description of symptoms (e.g., redness, swelling, pain, fever)
• Where on the body the reaction occurred
• Name of the polynucleotide product, if known
• Batch or lot number (often on packaging or clinic records)
• Name and qualification of the practitioner
• Clinic or venue where the injection took place
• Any steps taken after the reaction (e.g., medical advice, medication)
• Photographs of the reaction, if possible, to document visible effects

Recording these details may feel burdensome, but it can make a significant difference to your care. For example, batch numbers can help identify if a particular lot is associated with more frequent reactions. If you do not have access to all the information, record what you can. If you return to the clinic or practitioner, ask if they can provide additional details from their records. Keeping a symptom diary for several days after the reaction can also be useful, especially if symptoms change or progress over time.

How to Report Using the MHRA Yellow Card Scheme

The MHRA Yellow Card scheme is the UK’s system for reporting suspected side effects and adverse incidents involving medicines and medical devices, including unlicensed injectables like polynucleotides. Anyone can submit a report: patients, carers, and practitioners. The process involves completing an online or paper form, providing the details listed above, and describing the event clearly. The MHRA reviews all reports to detect safety signals and may issue safety notices or update guidance based on patterns in adverse events. While reporting does not guarantee individual follow-up, it contributes to the broader safety database. The scheme does not require a prescription or product licence for reporting.

To report, search for the "MHRA Yellow Card" and follow the instructions on the official site. You can also ask your healthcare provider to submit a report on your behalf. The form will prompt you for information about the product, the reaction, and your medical history. If you are unsure about any detail, provide as much as you can. You will receive a confirmation after submission, and you can keep a copy for your records. The MHRA may contact you for clarification if needed, but most reports are used for aggregate data analysis.

Step	What to Do
1	Record details (see above)
2	Access the MHRA Yellow Card scheme (search "MHRA Yellow Card")
3	Complete the online or paper form
4	Submit and keep a copy for your records

What If the Product Is Not Licensed?

Polynucleotide injectables are not currently licensed medicines in the UK. This means they are not included in the MHRA’s regular monitoring for licensed products, but adverse events can and should still be reported. The Yellow Card scheme accepts reports for unlicensed medicines, medical devices, and cosmetic injectables. Reporting is especially important for these substances, as evidence is developing and regulatory oversight relies on voluntary reporting to identify concerns. Even if the product is unlabelled or the batch number is unknown, a report can still be submitted with whatever information is available.

Unlicensed products are sometimes used in cosmetic practice before sufficient evidence has been gathered for licensing. As such, there may be less robust data on possible side effects or complications. By reporting any reaction, you help regulators build a clearer picture of the risks. This is also true if you are unsure whether the product was a polynucleotide injectable or another type of injectable. If in doubt, err on the side of reporting.

If you discover after the fact that the product was not licensed, this does not affect your right or ability to report. The MHRA encourages reporting of all suspected adverse reactions, regardless of product status.

What Happens After You Report?

After you submit a report to the MHRA Yellow Card scheme, the information is reviewed by safety experts. If a trend is observed, such as multiple reports of a particular reaction linked to a specific product or batch, the MHRA may investigate further. This could result in safety alerts, guidance updates, or, in rare cases, product withdrawal. You may not receive individual feedback unless more information is required, but your report remains valuable for ongoing safety monitoring. The process is confidential and will not affect your access to care.

The MHRA uses reported data to monitor for unexpected patterns, such as clusters of similar reactions or an increase in severity. If a safety issue is identified, the MHRA may work with clinics, practitioners, and manufacturers to address the risk. This can include issuing safety communications, updating professional guidance, or requesting further investigation into the product’s safety. Individual reports are anonymised in published summaries, and your personal details are not shared without your consent.

Even if your experience does not lead to immediate regulatory action, your report helps build the overall safety profile for polynucleotide injectables, which is essential for future users and for the development of safer products.

What to Do If You Need Immediate Help

If you experience severe or rapidly worsening symptoms (such as difficulty breathing, widespread rash, or facial swelling), seek emergency medical attention. For milder reactions, contact your practitioner or GP for advice. Record and report the event through the Yellow Card scheme regardless of severity, as even minor side effects contribute to the evidence base. Always retain any packaging or aftercare information provided at the time of treatment, as these may contain essential batch or product details.

In urgent situations, do not delay seeking help in order to record details or submit a report. Your health and safety take priority. Once you are stable and able, complete your records and submit a report. If you are unsure whether your symptoms are serious, err on the side of caution and seek professional advice. Practitioners are accustomed to handling post-injection reactions and can advise on appropriate next steps. If you are treated in hospital, inform the medical team about the injectable and provide any details you have recorded.

Decision Rule: Should I Report a Reaction?

Situation	Recommended Action
Any unexpected or concerning symptom after injection	Record and report via MHRA Yellow Card
Severe or life-threatening reaction	Seek emergency help, then report
Known minor side effect (e.g., mild bruising)	Optional, but reporting helps build evidence
Uncertainty about product or batch	Report with available information

This decision rule can be used as a quick reference. In general, if you are unsure whether to report, it is better to submit a report than not to. The MHRA values all reports, even those that seem minor or incomplete.

Limits of This Guidance

This guidance addresses recording and reporting reactions to polynucleotide injectables in the UK only. It does not cover diagnosis or management of medical emergencies, nor does it apply to vesicle or exosome injectables (covered by exosomaltherapy.co.uk). It is not a substitute for professional medical advice. For legal or insurance concerns, consult the relevant authority or a qualified professional. The reporting process may differ in other countries or for other substance classes.

People who have had injectables outside the UK, or those who are unsure of the substance used, may need to seek guidance from local authorities. This information is also not intended for use by practitioners as a replacement for their own professional reporting obligations, which may be governed by additional regulatory or insurance requirements. The guidance does not address compensation or complaints processes, which are separate from safety reporting.